#BEGIN_DRUGCARD DB02758

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H11NO2

# Chemical_IUPAC_Name:
3-(1H-indol-3-yl)propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Indolylpropionic Acid

# HET_ID:
IOP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H11NO2/c13-11(14)6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6H2,(H,13,14)

# InChI_Key:
InChIKey=GOLXRNDWAUTYKT-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2758

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
189.2105

# Molecular_Weight_Mono:
189.078978601

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1AHF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.04

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
7.27e-01 g/l

# Primary_Accession_No:
DB02758

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3744

# PubChem_Substance_ID:
46507621

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01908

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)CCC1=CNC2=CC=CC=C12

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:27 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X03629

# Drug_Target_1_GenBank_ID_Protein:
41011

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
aspC

# Drug_Target_1_Gene_Sequence:
>1191 bp
ATGTTTGAGAACATTACCGCCGCTCCTGCCGACCCGATTCTGGGCCTGGCCGATCTGTTT
CGTGCCGATGAACGTCCCGGCAAAATTAACCTCGGGATTGGTGTCTATAAAGATGAGACG
GGCAAAACCCCGGTACTGACCAGCGTGAAAAAGGCTGAACAGTATCTGCTCGAAAATGAA
ACCACCAAAAATTACCTCGGCATTGACGGCATCCCTGAATTTGGTCGCTGCACTCAGGAA
CTGCTGTTTGGTAAAGGTAGCGCCCTGATCAATGACAAACGTGCTCGCACGGCACAGACT
CCGGGGGGCACTGGCGCACTACGCGTGGCTGCCGATTTCCTGGCAAAAAATACCAGCGTT
AAGCGTGTGTGGGTGAGCAACCCAAGCTGGCCGAACCATAAGAGCGTCTTTAACTCTGCA
GGTCTGGAAGTTCGTGAATACGCTTATTATGATGCGGAAAATCACACTCTTGACTTCGAT
GCACTGATTAACAGCCTGAATGAAGCTCAGGCTGGCGACGTAGTGCTGTTCCATGGCTGC
TGCCATAACCCAACCGGTATCGACCCTACGCTGGAACAATGGCAAACACTGGCACAACTC
TCCGTTGAGAAAGGCTGGTTACCGCTGTTTGACTTCGCTTACCAGGGTTTTGCCCGTGGT
CTGGAAGAAGATGCTGAAGGACTGCGCGCTTTCGCGGCTATGCATAAAGAGCTGATTGTT
GCCAGTTCCTACTCTAAAAACTTTGGCCTGTACAACGAGCGTGTTGGCGCTTGTACTCTG
GTTGCTGCCGACAGTGAAACCGTTGATCGCGCATTCAGCCAAATGAAAGCGGCGATTCGC
GCTAACTACTCTAACCCACCAGCACACGGCGCTTCTGTTGTTGCCACCATCCTGAGCAAC
GATGCGTTACGTGCGATTTGGGAACAAGAGCTGACTGATATGCGCCAGCGTATTCAGCGT
ATGCGTCAGTTGTTCGTCAATACGCTGCAGGAAAAAGGCGCAAACCGCGACTTCAGCTTT
ATCATCAAACAGAACGGCATGTTCTCCTTCAGTGGCCTGACAAAAGAACAAGTGCTGCGT
CTGCGCGAAGAGTTTGGCGTATATGCGGTTGCTTCTGGTCGCGTAAATGTGGCCGGGATG
ACACCAGATAACATGGCTCCGCTGTGCGAAGCGATTGTGGCAGTGCTGTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
1868057	Inoue K, Kuramitsu S, Okamoto A, Hirotsu K, Higuchi T, Kagamiyama H: Site-directed mutagenesis of Escherichia coli aspartate aminotransferase: role of Tyr70 in the catalytic processes. Biochemistry. 1991 Aug 6;30(31):7796-801.
1993208	Danishefsky AT, Onnufer JJ, Petsko GA, Ringe D: Activity and structure of the active-site mutants R386Y and R386F of Escherichia coli aspartate aminotransferase. Biochemistry. 1991 Feb 19;30(7):1980-5.
2007566	Yano T, Kuramitsu S, Tanase S, Morino Y, Hiromi K, Kagamiyama H: The role of His143 in the catalytic mechanism of Escherichia coli aspartate aminotransferase. J Biol Chem. 1991 Apr 5;266(10):6079-85.
2513875	Smith DL, Almo SC, Toney MD, Ringe D: 2.8-A-resolution crystal structure of an active-site mutant of aspartate aminotransferase from Escherichia coli. Biochemistry. 1989 Oct 3;28(20):8161-7.
3298240	Kondo K, Wakabayashi S, Kagamiyama H: Structural studies on aspartate aminotransferase from Escherichia coli. Covalent structure. J Biol Chem. 1987 Jun 25;262(18):8648-57.
3521591	Fotheringham IG, Dacey SA, Taylor PP, Smith TJ, Hunter MG, Finlay ME, Primrose SB, Parker DM, Edwards RM: The cloning and sequence analysis of the aspC and tyrB genes from Escherichia coli K12. Comparison of the primary structures of the aspartate aminotransferase and aromatic aminotransferase of E. coli with those of the pig aspartate aminotransferase isoenzymes. Biochem J. 1986 Mar 15;234(3):593-604.
3897210	Kuramitsu S, Okuno S, Ogawa T, Ogawa H, Kagamiyama H: Aspartate aminotransferase of Escherichia coli: nucleotide sequence of the aspC gene. J Biochem (Tokyo). 1985 Apr;97(4):1259-62.
6378205	Kondo K, Wakabayashi S, Yagi T, Kagamiyama H: The complete amino acid sequence of aspartate aminotransferase from Escherichia coli: sequence comparison with pig isoenzymes. Biochem Biophys Res Commun. 1984 Jul 18;122(1):62-7.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9891001	Oue S, Okamoto A, Yano T, Kagamiyama H: Redesigning the substrate specificity of an enzyme by cumulative effects of the mutations of non-active site residues. J Biol Chem. 1999 Jan 22;274(4):2344-9.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2249

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
43574

# Drug_Target_1_Name:
Aspartate aminotransferase

# Drug_Target_1_Number_of_Residues:
396

# Drug_Target_1_PDB_ID:
1CQ8

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_1_Protein_Sequence:
>Aspartate aminotransferase
MFENITAAPADPILGLADLFRADERPGKINLGIGVYKDETGKTPVLTSVKKAEQYLLENE
TTKNYLGIDGIPEFGRCTQELLFGKGSALINDKRARTAQTPGGTGALRVAADFLAKNTSV
KRVWVSNPSWPNHKSVFNSAGLEVREYAYYDAENHTLDFDALINSLNEAQAGDVVLFHGC
CHNPTGIDPTLEQWQTLAQLSVEKGWLPLFDFAYQGFARGLEEDAEGLRAFAAMHKELIV
ASSYSKNFGLYNERVGACTLVAADSETVDRAFSQMKAAIRANYSNPPAHGASVVATILSN
DALRAIWEQELTDMRQRIQRMRQLFVNTLQEKGANRDFSFIIKQNGMFSFSGLTKEQVLR
LREEFGVYAVASGRVNVAGMTPDNMAPLCEAIVAVL

# Drug_Target_1_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_1_SwissProt_ID:
P00509

# Drug_Target_1_SwissProt_Name:
AAT_ECOLI

# Drug_Target_1_Synonyms:
ASPAT
EC 2.6.1.1
Transaminase A

# Drug_Target_1_Theoretical_pI:
5.50

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Y08272

# Drug_Target_2_GenBank_ID_Protein:
1806263

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
tyrB

# Drug_Target_2_Gene_Sequence:
>1185 bp
ATGCTGGGCAATCTGAAACCGCAGGCCCCCGACAAGATCCTGGCCCTGATGGGCGAATTC
AGGGCCGATCCCCGCCAGGGCAAGATCGACCTGGGCGTGGGGGTCTACAAGGATGCCACC
GGCCACACCCCGATCATGCGGGCCGTCCACGCCGCCGAGCAGCGCATGCTGGAAACCGAG
ACCACCAAGACCTATGCCGGCCTCTCGGGCGAGCCCGAGTTCCAAAAGGCCATGGGCGAG
CTGATCCTGGGCGACGGACTGAAATCCGAGACCACCGCGACGCTGGCGACGGTCGGCGGC
ACCGGCGCCCTCCGGCAGGCGCTGGAACTGGCGCGCATGGCGAACCCGGACCTGCGGGTC
TTCGTCAGCGATCCGACCTGGCCGAACCATGTCTCGATCATGAATTTCATGGGCCTGCCG
GTGCAGACCTATCGCTATTTCGATGCCGAGACCCGCGGCGTCGATTTCGAGGGCATGAAG
GCCGACCTCGCCGCCGCGAAAAAGGGCGACATGGTGCTGCTGCACGGCTGCTGCCACAAC
CCGACCGGCGCCAACCTGACGCTGGATCAATGGGCCGAGATCGCCTCGATCCTGGAAAAG
ACCGGCGCGCTGCCGCTGATCGACCTGGCCTATCAGGGCTTCGGCGACGGGCTGGAAGAG
GACGCGGCCGGCACCCGGCTGATCGCCTCGCGCATCCCCGAGGTGCTGATCGCGGCCTCG
TGCAGCAAGAACTTCGGCATCTACCGCGAACGCACCGGCTGCCTGCTGGCGCTTTGCGCC
GATGCGGCGACCAGGGAGCTGGCGCAGGGCGCCATGGCCTTCCTGAACCGCCAGACCTAT
TCCTTCCCGCCCTTCCACGGCGCCAAGATCGTCTCGACCGTGCTGACCACGCCCGAACTG
CGCGCCGACTGGATGGCCGAGCTGGAAGCGGTGCGCAGCGGCATGCTGCGCCTGCGCGAG
CAATTGGCGGGCGAGTTGCGCGATCTCAGCGGTTCGGACCGTTTCGGCTTCGTGGCCGAG
CATCGCGGCATGTTCTCGCGCCTGGGCGCCACGCCCGAACAGGTCAAGCGCATCAAGGAA
GAGTTCGGCATCTACATGGTGGGCGATTCGCGCATCAACATCGCCGGGCTGAACGACAAC
ACCATCCCGATCCTGGCCCGCGCTATCATCGAGGTGGGGGTCTAA

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
9058208	Oue S, Okamoto A, Nakai Y, Nakahira M, Shibatani T, Hayashi H, Kagamiyama H: Paracoccus denitrificans aromatic amino acid aminotransferase: a model enzyme for the study of dual substrate recognition mechanism. J Biochem (Tokyo). 1997 Jan;121(1):161-71.
9665848	Okamoto A, Nakai Y, Hayashi H, Hirotsu K, Kagamiyama H: Crystal structures of Paracoccus denitrificans aromatic amino acid aminotransferase: a substrate recognition site constructed by rearrangement of hydrogen bond network. J Mol Biol. 1998 Jul 17;280(3):443-61.
9930977	Okamoto A, Ishii S, Hirotsu K, Kagamiyama H: The active site of Paracoccus denitrificans aromatic amino acid aminotransferase has contrary properties: flexibility and rigidity. Biochemistry. 1999 Jan 26;38(4):1176-84.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2537

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
42733

# Drug_Target_2_Name:
Aromatic-amino-acid aminotransferase

# Drug_Target_2_Number_of_Residues:
394

# Drug_Target_2_PDB_ID:
2AY7

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_2_Protein_Sequence:
>Aromatic-amino-acid aminotransferase
MLGNLKPQAPDKILALMGEFRADPRQGKIDLGVGVYKDATGHTPIMRAVHAAEQRMLETE
TTKTYAGLSGEPEFQKAMGELILGDGLKSETTATLATVGGTGALRQALELARMANPDLRV
FVSDPTWPNHVSIMNFMGLPVQTYRYFDAETRGVDFEGMKADLAAAKKGDMVLLHGCCHN
PTGANLTLDQWAEIASILEKTGALPLIDLAYQGFGDGLEEDAAGTRLIASRIPEVLIAAS
CSKNFGIYRERTGCLLALCADAATRELAQGAMAFLNRQTYSFPPFHGAKIVSTVLTTPEL
RADWMAELEAVRSGMLRLREQLAGELRDLSGSDRFGFVAEHRGMFSRLGATPEQVKRIKE
EFGIYMVGDSRINIAGLNDNTIPILARAIIEVGV

# Drug_Target_2_Reaction:
an aromatic amino acid + 2-oxoglutarate = an aromatic oxo acid + L-glutamate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Shows activities toward both dicarboxylic and aromatic substrates

# Drug_Target_2_SwissProt_ID:
P95468

# Drug_Target_2_SwissProt_Name:
TYRB_PARDE

# Drug_Target_2_Synonyms:
ARAT
AROAT
EC 2.6.1.57

# Drug_Target_2_Theoretical_pI:
5.49

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted

# Drug_Target_3_Chromosome_Location:
1

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AF189279

# Drug_Target_3_GenBank_ID_Protein:
7108923

# Drug_Target_3_GeneCard_ID:
PLA2G2E

# Drug_Target_3_Gene_Name:
PLA2G2E

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Involved in calcium ion binding

# Drug_Target_3_General_References:
10681567	Suzuki N, Ishizaki J, Yokota Y, Higashino K, Ono T, Ikeda M, Fujii N, Kawamoto K, Hanasaki K: Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem. 2000 Feb 25;275(8):5785-93.
16710414	Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21.

# Drug_Target_3_HGNC_ID:
GNC:13414

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6270

# Drug_Target_3_Locus:
1p36.13

# Drug_Target_3_Molecular_Weight:
15988.5

# Drug_Target_3_Name:
Group IIE secretory phospholipase A2

# Drug_Target_3_Number_of_Residues:
142

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00068	Phospholip_A2_1

# Drug_Target_3_Protein_Sequence:
>Group IIE secretory phospholipase A2
MKSPHVLVFLCLLVALVTGNLVQFGVMIEKMTGKSALQYNDYGCYCGIGGSHWPVDQTDW
CCHAHDCCYGRLEKLGCEPKLEKYLFSVSERGIFCAGRTTCQRLTCECDKRAALCFRRNL
GTYNRKYAHYPNKLCTGPTPPC

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-19

# Drug_Target_3_Specific_Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids

# Drug_Target_3_SwissProt_ID:
Q9NZK7

# Drug_Target_3_SwissProt_Name:
PA2GE_HUMAN

# Drug_Target_3_Synonyms:
GIIE sPLA2
Phosphatidylcholine 2-acylhydrolase GIIE
sPLA(2)-IIE

# Drug_Target_3_Theoretical_pI:
8.28

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB02758
